UAE’s Mubadala Healthcare contributes to UK COVID-19 diabetes drug trial

UAE’s Mubadala Healthcare contributes to UK COVID-19 diabetes drug trial

The Arcadia trial began on Sept. 29 and involved hospitalized patients with mild to moderate COVID-19 symptoms. (File/Reuters)

Short Url

UAE's Mubadala Healthcare contributes to UK COVID-19 diabetes drug trial

The trial, known as Arcadia, was approved following preclinical research

If successful, it could be prescribed by doctors for people with diabetes

Updated 09 November 2020

Follow @arabnews

DUBAI: A leading UAE health care provider revealed that it was contributing to a British-based drug trial that will help patients with diabetes overcome the effects of the coronavirus disease (COVID-19).

Mubadala Healthcare is part-funding the trial of an immune-dampening drug approved by the UK's Medicines and Healthcare products Regulatory Agency.

The trial, known